Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™
The patent claims, include self-centering fluid bag hangers and density compensation mechanisms for enhanced accuracy in fluid management. Ease of use is increased with self-sealing access ports for easy configuration of various dialysis modes, streamlining the treatment process. Additionally, reliability is boosted by a temperature-adjusting auto-clamp that ensures secure seals, reducing the risk of leaks and enhancing overall system dependability.
"We are thrilled to announce the issuance of this patent, which represents a significant milestone in the development of our pediatric continuous renal replacement therapy, Vivian," said
About Vivian
Nuwellis is currently developing Vivian, a new, fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children with limited or no kidney function. Vivian is not yet cleared by the FDA. This development effort was funded in part by a
About Nuwellis
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2024 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
CONTACTS
Investors:
ir@nuwellis.com
Source: Nuwellis, Inc.